Oncodesign Services

Oncodesign Services is a well-established, France-based CRO providing end-to-end drug discovery and preclinical development services, with a strong historical focus on oncology and a growing portfolio in inflammatory diseases. It differentiates itself through integrated service packages (e.g., DRIVE-IDDS, INPACT) and a unique radiopharmaceutical development platform that includes bioconjugation and in vivo pharmaco-imaging. The company is recognized for its translational pharmacology expertise, as evidenced by winning 'Oncology CRO of the Year 2025 – France,' and operates as a key partner for biopharma companies advancing novel therapeutics.

Integrated drug discovery and preclinical services platform featuring a specialized Bioconjugation and Radiochemistry Platform for radiopharmaceutical development (including access to imaging/therapeutic isotopes, bioconjugation strategies, and in vivo pharmaco-imaging), supported by AI/ML integration, structural biology, medicinal chemistry, DMPK, and extensive in vivo translational models.

Oncodesign Services competes with large, global full-service CROs (e.g., Charles River, LabCorp) and numerous niche preclinical CROs specializing in oncology or pharmacology. Its differentiated radiopharmaceutical development platform places it in a more specialized, less crowded segment, competing with a handful of expert service providers and in-house capabilities at large pharma.